Biotricity Inc BTCY

Healthcare Medical Devices

Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.

NDAQ:BTCY - Post by User

Biotricity Inc

<< Previous

Bullboard Posts

Next >>

Post by stargazer1on Jul 24, 2023 6:12pm

73 Views

Post# 35554996

BTCY is taking off on a multi-year tear

Biotricity, Inc. (BTCY)

At close: 4:00 PM EDT (Eastern Daylight Time)

$3.17 + $0.22 (+7.46%)

After hours: 4:44 PM EDT

$3.25 + $0.08

Then, 16 minutes later

After hours: 5:00 PM EDT

$3.30 + $0.13

After hours: 5:15 PM EDT

$3.3900 + $0.22 (which is how much it climbed in the entire day's trading = + 6.94% from the close

Previously

For the first fiscal quarter that ended June 30, 2023, the Company reported an increase in revenue which represents growth of over 40% Year Over Year from the corresponding prior-year quarter.

Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, commented, "Based on robust first-quarter revenue growth and our early read on the quarter's sales and operating metric trends - including customer retention -- I am fully confident our business will continue to scale as planned and show strong growth throughout the fiscal year 2024.

"Our products and biosphere platform model, and vertical sales strategy of complementary products, continues to strengthen," Dr. Waqaas added. "Since launching our Biocare app in January of this year, we have had over 10,000 downloads. Our second product -- Biotres^TM- is rapidly gaining traction industrywide with new and existing customer purchases exceeding our internal forecast. It will set a company record for its $2 million run rate."

Bitricity will continue accelerating its growth in the coming years as it expands its presence in the U.S. market and additionally, expands globally.